ERRα (E1G1J) Rabbit mAb #13826
- WB
- ChIP
Supporting Data
| REACTIVITY | H M R Mk |
| SENSITIVITY | Endogenous |
| MW (kDa) | 50 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
- ChIP-Chromatin Immunoprecipitation
Species Cross-Reactivity Key:
- H-Human
- M-Mouse
- R-Rat
- Mk-Monkey
Product Information
Product Usage Information
For optimal ChIP and ChIP-seq results, use 10 μl of antibody and 10 μg of chromatin (approximately 4 x 106 cells) per IP. This antibody has been validated using SimpleChIP® Enzymatic Chromatin IP Kits.
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Chromatin IP | 1:50 |
| Chromatin IP-seq | 1:50 |
Storage
Protocol
Specificity / Sensitivity
Species Reactivity:
The antigen sequence used to produce this antibody shares 100% sequence homology with the species listed here, but reactivity has not been tested or confirmed to work by CST. Use of this product with these species is not covered under our Product Performance Guarantee.
Species predicted to react based on 100% sequence homology:
Source / Purification
Background
Estrogen-related receptor α (ERRα/NR3B1) is an orphan nuclear receptor that controls transcription of genes involved in fatty acid oxidation, glucose metabolism, and mitochondrial biogenesis (1,2). The receptor protein contains a non-conserved amino terminal domain (NTD), a central zinc finger DNA binding domain, and a ligand-binding domain. The carboxy-terminal AF2 helix motif of ERRα contains binding sites for nuclear receptor coactivators PGC-1α and PGC-1β (3-5). Research studies demonstrate that ERRα transcriptional activity is regulated through phosphorylation and sumoylation within the NTD (6). ERRα is ubiquitously expressed, with strong expression observed in heart, kidneys, skeletal muscle, and other high metabolic demand tissues (2). Additional studies indicate that ERRα is coexpressed in breast tumors with unfavorable biomarkers (7). The pharmacologic inhibition of ERRα activity in breast cancer might serve as a valuable therapeutic approach (8,9).
- Giguère, V. (2008) Endocr Rev 29, 677-96.
- Giguère, V. et al. (1988) Nature 331, 91-4.
- Huss, J.M. et al. (2002) J Biol Chem 277, 40265-74.
- Schreiber, S.N. et al. (2003) J Biol Chem 278, 9013-8.
- Kamei, Y. et al. (2003) Proc Natl Acad Sci U S A 100, 12378-83.
- Tremblay, A.M. et al. (2008) Mol Endocrinol 22, 570-84.
- Ariazi, E.A. et al. (2002) Cancer Res 62, 6510-8.
- Chang, C.Y. et al. (2011) Cancer Cell 20, 500-10.
- Deblois, G. et al. (2009) Cancer Res 69, 6149-57.
- Lanvin, O. et al. (2007) J Biol Chem 282, 28328-34.
- Willy, P.J. et al. (2004) Proc Natl Acad Sci U S A 101, 8912-7.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.